656804-73-8

Usage

Uses

Used in Organic Synthesis:
1,2-Benzenediol, 4-bromo-5-fluoro(9CI) is used as a building block in organic synthesis for the creation of biologically active compounds and drug-like molecules. Its unique structure and functional groups allow for various chemical reactions, enabling the synthesis of a wide range of organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1,2-Benzenediol, 4-bromo-5-fluoro(9CI) is utilized for the development of new drugs and medications. Its potential applications in drug discovery make it a valuable compound for researchers working on the design and synthesis of novel therapeutic agents.
Used in Drug Development:
1,2-Benzenediol, 4-bromo-5-fluoro(9CI)'s stability and unique properties make it suitable for use in the development of new drugs and medications. Researchers can leverage its characteristics to create innovative pharmaceutical formulations with improved efficacy and safety profiles.
Used in Research and Development:
1,2-Benzenediol, 4-bromo-5-fluoro(9CI) is an important compound for research and development purposes across various industries. Its potential uses and applications make it a valuable asset for scientists and researchers working on the discovery and development of new chemical entities and pharmaceutical products.

Upstream product

• 398-62-9 4-fluoroveratrole 
• 886510-25-4 4-bromo-5-fluoro-2-methoxyphenol 
• 367-32-8 4-fluoropyrocatechol 
• 1095544-81-2 C₈H₈BrFO₂ 

Downstream Products

• 94670-75-4 5-bromo-6-fluorobenzo-1,3-dioxole 
• 656804-74-9 5-bromo-2-(2,4-dichlorophenyl)-6-fluoro-2-(4-fluorophenyl)benzo[1,3]dioxole 
• 656805-52-6 5-bromo-6-fluoro-2,2-diphenylbenzo[1,3]dioxole 
• 917751-96-3 5-bromo-2-(2,4-dichlorophenyl)-6-fluoro-2-(2-fluorophenyl)benzo[1,3]dioxole 
• 1020092-91-4 (R)-5-bromo-2-(2,4-dichlorophenyl)-6-fluoro-2-(4-fluorophenyl)benzo[1,3]dioxole 
• 656806-12-1 5-bromo-2,2-bis(2,4-difluorophenyl)-6-fluorobenzo[1,3]dioxole 
• 656805-49-1 5-bromo-6-fluoro-2,2-bis(4-fluorophenyl)benzo[1,3]dioxole 
• 1338708-66-9 C₂₃H₂₁FO₆ 
• 1338708-65-8 C₂₂H₂₀BrFO₄ 

Relevant academic research and scientific papers

INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES

Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC)PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES

Novel 4-amino-6-(heterocyclic)picolinic acids and their derivatives and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their derivatives are useful to control undesirable vegetation.

New pyrrolidine derivatives, pharmaceutical compositions and uses thereof

Pyrrolidine derivatives of the formula and their use as medicaments for the treatment of obesity and type 2 diabetes.

NEW PYRROLIDINE DERIVATIVES AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS

The invention relates to new pyrrolidine derivatives of the formula (I) to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS

The invention relates to new azetidine derivatives of the formula (I) wherein Ar1, Ar2, X, R, T and L are as defined in the description, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

AZETIDINE DERIVATIVES

Azetidine derivatives of which the following is exemplary and their use in the treatment of obesity, diabetes or dyslipidemia.

NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The invention relates to new piperidine derivatives of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Benzodioxoles: Novel cannabinoid-1 receptor inverse agonists for the treatment of obesity

The application of the evolutionary fragment-based de novo design tool TOPology Assigning System (TOPAS), starting from a known CB1R (CB-1 receptor) ligand, followed by further refinement principles, including pharmacophore compliance, chemical tractabili

Heterocyclic CB1 receptor antagonists

The present invention relates to compounds of formula wherein R1 and R2 are each independently hydrogen or halogen. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of

Stereospecifically substituted benzo[1,3]dioxolyl derivatives

The present invention relates to compounds of formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, for use as therapeutically active substances. The compounds are